Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?

[1]  H. Hansen,et al.  Efficacy of low‐dose topotecan in second‐line treatment for patients with epithelial ovarian carcinoma , 2002, Cancer.

[2]  R. Ozols.  Recurrent ovarian cancer: evidence-based treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Bauknecht,et al.  Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Markman.  Why study third-, fourth-, fifth-, ...line chemotherapy of ovarian cancer? , 2001, Gynecologic oncology.

[5]  A. Pfleiderer.  Is there any progress in the outcome of patients suffering from ovarian cancer? Treatment strategies since 1957. , 2001, Gynecologic oncology.

[6]  G Molenberghs,et al.  Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes , 2001, Statistics in medicine.

[7]  H. Hansen,et al.  Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. , 2001, Gynecologic oncology.

[8]  M. Markman.  Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment? , 2001, Gynecologic oncology.

[9]  R. Simon,et al.  A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. , 2000, Journal of the National Cancer Institute.

[10]  R. Pazdur.  Response rates, survival, and chemotherapy trials. , 2000, Journal of the National Cancer Institute.

[11]  H. V. van Houwelingen,et al.  Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Deppe,et al.  Advances in ovarian cancer chemotherapy. , 2000, Current opinion in oncology.

[13]  Geert Molenberghs,et al.  Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.

[14]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[15]  A. Cesano,et al.  Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. , 1999, International journal of oncology.

[16]  M. Gore,et al.  Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Markman.  "Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer? , 1998, Gynecologic oncology.

[18]  B. Escudier,et al.  Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M Buyse,et al.  On the relationship between response to treatment and survival time. , 1996, Statistics in medicine.

[20]  P. Kenemans,et al.  CA 125: A valid marker in ovarian carcinoma patients treated with paclitaxel? , 1996, Cancer.

[21]  H E Lambert,et al.  Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Armitage,et al.  Treatment of non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[23]  J L Pater,et al.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Markman.  Clinical response versus clinical benefit in oncology: not necessarily equivalent terms , 2005, Journal of Cancer Research and Clinical Oncology.

[26]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[27]  M. Gore,et al.  Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  J. Neijt,et al.  Advanced epithelial ovarian cancer: 1998 consensus statements. , 1993 .

[29]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.